



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Evaluation of *in vitro* activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study



Felipe Francisco Tuon ^{a,*}, Juliette Cieslinski^a, Suellen da Silva Rodrigues^b,
Fernando Brandão Serra^b, Marina Della-Negra de Paula^b

^a Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Laboratório de Doenças Infeciosas Emergentes, Curitiba, PR, Brazil

^b Merck Sharp Dohme Brazil, São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Received 9 August 2019

Accepted 8 April 2020

Available online 28 April 2020

Keywords:

Ceftolozane

tazobactam

Pseudomonas aeruginosa

Enterobacteriales

Drug Resistance

Antimicrobial Resistance

Antimicrobial Susceptibility Test

ABSTRACT

Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens. This study aimed to evaluate the *in vitro* activity of ceftolozane–tazobactam against clinical bacterial isolates from Brazil.

Methods: A total of 673 Gram-negative bacterial isolates including *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and other *Enterobacteriales* collected from 2016 to 2017 were tested, most of them isolated from patients in intensive care units. Minimum inhibitory concentrations (MIC_{50/90}) were determined by broth microdilution for amikacin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftolozane–tazobactam, ceftazidime, ceftriaxone, ciprofloxacin, colistin, ertapenem, imipenem, levofloxacin, meropenem, and piperacillin-tazobactam using dried panels. Antimicrobial susceptibility results were interpreted according to Clinical and Laboratory Standards Institute criteria.

Results: Susceptibility rates to ceftolozane–tazobactam ranged from 40.4% to 94.9%. *P. aeruginosa* susceptibility rate to ceftolozane–tazobactam was 84.9% (MIC_{50/90}, 1/16 µg/mL) and 99.2% to colistin. For *E. coli*, ceftolozane–tazobactam inhibited 94.9% (MIC_{50/90}, 0.25/1 µg/mL) of the microorganisms. The susceptibility rate of *K. pneumoniae* to ceftolozane–tazobactam was 40.4% (MIC_{50/90}, 16/>32 µg/mL). Other *Enterobacteriales* have shown susceptibility rates of 81.1% (MIC_{50/90}, 0.5/16 µg/mL) to ceftolozane–tazobactam, 93.9% to meropenem, 90.9% to amikacin (90.9%), and 88.6% to ertapenem. In non-carbapenemase producing isolates, AmpC mutations were found three isolates.

Conclusions: Ceftolozane–tazobactam has shown relevant activity against a large variety of the analyzed microorganisms collected from multiple centers in Brazil, showing promising results even in multidrug resistant strains.

© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: felipe.tuon@pucpr.br (F.F. Tuon).

<https://doi.org/10.1016/j.bjid.2020.04.004>

1413-8670/© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The emergence of antibiotic resistance is increasing and represents one of the major threats to global health today. Infections caused by multidrug resistant microorganisms cause relevant clinical and economic impact leading to increased hospital stays, costs and mortality.¹ The Centers for Disease Control and Prevention (CDC) points that about two million people in the USA present with infections caused by bacteria resistant to at least one antimicrobial agent of choice each year, leading to at least 23,000 deaths annually.² Healthcare-associated infections account for a high incidence of multidrug resistant microorganisms due to recurrent overuse and misuse of these medications, high density of susceptible hosts, and increased odds of transmission among patients.^{3,4}

In 2017, the World Health Organization (WHO) published a list of pathogens with priority demand for new antibiotics due to antimicrobial resistant profile. Amongst the critical priority pathogens were carbapenem-resistant *Pseudomonas aeruginosa*, and carbapenem and third-generation cephalosporins-resistant *Enterobacterales*, which includes *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter spp.*, *Serratia spp.*, *Proteus spp.*, *Providencia spp.*, and *Morganella spp.*⁵

P. aeruginosa has a leading role among infections caused by Gram-negative rods, especially in critically ill and immunocompromised patients, e.g. those who experienced extensive, high-degree burns.⁶ Treatment options are limited due to antimicrobial resistance, which permitted *P. aeruginosa* infections to become a serious issue causing a total of 51,000 healthcare-associated infections per year in the USA.^{7,8} In Brazil, *P. aeruginosa* is the fifth bacterial pathogen in bloodstream infections associated with central venous catheters in adult patients, accounting for 8.5% of this infection in 2016.⁹

Currently, eight categories of antibiotics are mainly used to treat *P. aeruginosa* infections such as aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillin with β -lactamase inhibitors, monobactams, fosfomycin, and polymyxin. However, Gram-negative bacilli like *P. aeruginosa* may present many mechanisms of antibiotic resistance, which can be expressed at the same time, including decrease in influx porin activity, increase in efflux pumps, production of altered penicillin-binding proteins and catalytic enzymes that inactivate antibiotics.^{7,10}

Meanwhile, *Enterobacterales* also represent a significant concern due to carbapenem-resistance.¹¹ Currently, therapies against carbapenem-resistant *Enterobacterales* include tigecycline, ceftazidime-avibactam, and other drugs not widely used recently such as colistin, fosfomycin, and aminoglycosides.¹¹

Few studies have reported the profile of new antibiotics in low-to middle income countries. Pfaller et al. reported the *in vitro* activity of ceftolozane-tazobactam and comparator agents against Latin American isolates *Enterobacterales* and *P. aeruginosa* from 2013 to 2015.¹² Considering the need for updated knowledge about susceptibility profile, especially regarding new antibiotics, this study aimed to evaluate the *in vitro* activity of ceftolozane-tazobactam against clinical bacterial isolates of *P. aeruginosa*, *E. coli*, *K. pneumoniae*, and other *Enterobacterales* from Brazil.

Materials and methods

Study design

This study evaluated the antibacterial activity and minimum inhibitory concentration of ceftolozane-tazobactam and 15 comparator compounds against a recent collection of Gram-negative bacterial isolates prospectively collected in 10 different centers in Brazil from 2016 to 2017. Centers were in the following Brazilian states: Bahia, Minas Gerais, Paraná, Rio de Janeiro, and São Paulo.

Bacterial isolates

The bacteria used in the analysis were selected from different participating sites across the country. Each site collected consecutive fresh clinical Gram-negative aerobic isolates composed only by: *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and other *Enterobacterales* (*Proteus mirabilis*, *Enterobacter cloacae*, and *K. oxytoca*). No more than 15% of the isolates ought to be retrieved from lower respiratory tract infections. The remainder were to be collected from complicated urinary infections and complicated intra-abdominal infections sources. Only isolates associated with infection were included in the study. Multiple organisms from one specimen were acceptable provided each was a unique initial Gram-negative bacillus, but only the first isolate of a particular species per patient for the entire collection period was accepted. Exclusion criteria were: non-target species; isolates from *in situ* drains or drainage bottles; isolates from stools or perirectal abscess; duplicate isolates (same genus and species) obtained from the same or different specimen even if they were obtained from the same or different body sites; duplicate isolates (same genus and species) obtained at any subsequent time from the same patient, regardless of susceptibility or phenotypic profile; and environmental samples (non-patient derived) or surveillance cultures taken for infection control purposes.

After initial identification of the isolates in the primary center, all isolates were stored in Tryptic Soy Broth with glycerol and frozen at -70 or -20 °C. All isolates were further sent for a reference laboratory (International Health Management Associates Inc.). All isolates were re-identified by the coordinator center using MALDI-TOF MS.

Minimum inhibitory concentration

MIC values were determined by broth microdilution according to CLSI guidelines for antimicrobials previously described, using dried panels prepared by Trek Diagnostics Systems Ltd. (East Grinstead, West Sussex, UK).^{13,14} Ceftolozane-tazobactam, amikacin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, ertapenem, imipenem, levofloxacin, and piperacillin-tazobactam were determined using broth microdilution as shown in Table 1.

Colonies were taken directly from a second-pass culture plate and prepared to a suspension equivalent of the 0.5 McFarland standard using normal saline. Inoculation of the MIC plates took place within 15 min after adjustment of the

Table 1 – Range and concentrations of compounds tested.

Compound	Test range (mg/L)
Amikacin	4–32
Aztreonam	1–16
Cefepime	1–32
Cefotaxime	1–32
Cefoxitin	2–16
Ceftolozane–tazobactam	0.06–32
Ceftazidime	1–32
Ceftriaxone	1–32
Ciprofloxacin	0.25–2
Colistin	1–4
Ertapenem	0.06–4
Imipenem	0.5–32
Levofloxacin	1–4
Meropenem	0.12–16
Piperacillin–tazobactam	2–64

inoculum suspension turbidity. The panels were incubated at 35 °C for 16–20 h before reading the MIC endpoints. Interpretive criteria followed CLSI 2017 guidelines for all compounds except colistin for which the EUCAST 2017 breakpoint was used for *Enterobacterales*.^{14,15} Quality control (QC) testing was performed each day of testing as specified by the CLSI using *E. coli* ATCC 25922, *P. aeruginosa* ATCC 27853, and *K. pneumoniae* ATCC 700603. All QC data were within CLSI approved ranges where available.¹⁴

Presence of carbapenemases in C/T resistant *P. aeruginosa*

Phenotypic detection of carbapenemases was performed by the Carba-NP (Repidec®) test, following manufacturer's protocol on all C/T non-susceptible isolates (MIC_{50/90} ≥8/4).

Molecular detection of carbapenemases was performed on all Carba-NP positive isolates by in-house conventional PCR assays, which targeted genes encoding the following groups of carbapenemases: KPC, NDM, VIM, IMP, and OXA-48.

Whole genome sequencing of resistant strains

Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). DNA quality was verified by agarose gel electrophoresis and quantified using Qubit 2.0 fluorometer (Invitrogen by Thermo Fisher Scientific, Life Technologies Italia, Monza, Italy). Paired-end libraries were prepared from 1 ng of total bacterial DNA using Nextera XT DNA Sample Preparation kit and Nextera XT Index kit (Illumina Inc., San Diego, California, U.S.A.). Library concentration and average fragment size were calculated by Qubit 2.0 fluorometer and Agilent 2100 bioanalyzer (Agilent technologies, Santa Clara, CA, U.S.A.). Sequences were obtained on the Illumina MiSeq platform (Illumina Inc., San Diego, California, U.S.A.) with 250 nt paired-end reads to achieve a coverage of about 30× per base, using MiSeq V3 flow cell.

Raw reads underwent a series of steps for quality filtering which included a general quality check and the trimming of low-quality ends. *De novo* assemblies were performed using CLC Genomics Workbench 8.1.0 software. Annotation was

Table 2 – Distribution of included isolates by species in Brazil.

Species	N	Percent (%)
<i>Escherichia coli</i>	216	32.1
<i>Klebsiella pneumoniae</i>	193	28.7
<i>Pseudomonas aeruginosa</i>	132	19.6
<i>Proteus mirabilis</i>	72	10.7
<i>Enterobacter cloacae</i>	38	5.6
<i>Klebsiella oxytoca</i>	11	1.6
<i>Klebsiella variicola</i>	4	0.6
<i>Klebsiella aerogenes</i>	3	0.4
<i>Enterobacter asburiae</i>	1	0.1
<i>Morganella morganii</i>	1	0.1
<i>Proteus vulgaris</i>	1	0.1
<i>Providencia rettgeri</i>	1	0.1
Total	673	100

done by using RAST server, and the presence of resistance determinants were determined by BLAST and ResFinder.

The genome of *P. aeruginosa* PAO1 (GenBank ID: NC_002516.2 https://www.ncbi.nlm.nih.gov/genome/187?genome_assembly_id=299953) was used as reference to look for known substitutions associated with C/T resistance in *AmpC* and its regulator, *AmpR*.

Statistical analysis

Data were analyzed using a descriptive approach through measures of central tendency and dispersion for continuous variables and measures of frequency for categorical variables. MIC_{50/90} were calculated.

Results

A total of 673 isolates from 10 sites were included during the study period. The clinical isolates were retrieved from intensive care units (ICU) (75%) and from non-ICU (25%).

Table 1 shows the antibiotics assessed, the range and concentration of each drug, and Table 2 shows the distribution of species tested. *E. coli* (N = 216; 32.1%), *K. pneumoniae* (N = 193; 28.7%), and *P. aeruginosa* (N = 132; 19.6%) were the most prevalent species.

Table 3 shows the susceptibility profile of different organisms to several antibiotics.

Considering the analysis performed for *P. aeruginosa*, the susceptibility rate to ceftolozane–tazobactam was 84.9%, with MIC_{50/90} values of 1/16 µg/mL (Table 3; Fig. 1). Colistin was the most active compound, with 99.2% of isolates susceptible (MIC_{50/90}, ≤1/≤1 µg/mL); cefepime, ciprofloxacin, and levofloxacin have also shown estimates above 60%.

Ceftolozane–tazobactam susceptibility rate against *E. coli* was 94.9%. Susceptibility rates to other antibiotics were 97.7% to amikacin, 97.2% to meropenem, 94.0% to ertapenem, and 91.7% to piperacillin–tazobactam. The activity of ceftolozane–tazobactam against *E. coli* was high (MIC_{50/90}, 0.25/1 µg/mL) (Table 3; Fig. 2).

Susceptibility rate of *K. pneumoniae* to ceftolozane–tazobactam was 40.4%, with weak activity against this microorganism (MIC_{50/90}, 16/>32 µg/mL), but

Table 3 – In vitro activity of ceftolozane–tazobactam and comparators against 673 isolates from Brazil.

Organism (n)	Antimicrobial	%S	%I	%R	MIC ₅₀	MIC ₉₀	Range	
<i>Pseudomonas aeruginosa</i> (132)	Ceftolozane–tazobactam	84.9	4.6	10.6	1	16	0.5–>32	
	Amikacin	84.9	3.0	12.1	≤4	>32	≤4–>32	
	Aztreonam	50.0	15.9	34.1	8	>16	2–>16	
	Cefepime	61.4	12.9	25.8	8	>32	≤1–>32	
	Ceftazidime	59.9	9.9	30.3	8	>32	≤1–>32	
	Ciprofloxacin	68.9	6.8	24.2	≤0.25	>2	≤0.25–>2	
	Colistin	99.2	–	0.8	≤1	≤1	≤1–4	
	Imipenem	53.0	6.1	40.9	2	32	≤0.5–>32	
	Levofloxacin	62.9	7.6	29.6	≤1	>4	≤1–>4	
	Meropenem	58.3	9.9	31.8	2	>16	≤0.12–>16	
<i>Escherichia coli</i> (216)	Piperacillin-tazobactam	55.3	14.4	30.3	16	>64	≤2–>64	
	Ceftolozane–tazobactam	94.9	2.3	2.8	0.25	1	≤0.06–>32	
	Amikacin	97.7	0.9	1.4	≤4	8	≤4–>32	
	Aztreonam	67.1	7.4	25.5	≤1	>16	≤1–>16	
	Cefepime	65.3	7.9	26.9	≤1	>32	≤1–>32	
	Cefotaxime	60.7	1.4	38.0	≤1	>32	≤1–>32	
	Cefoxitin	68.5	14.8	16.7	8	>16	≤2–>16	
	Ceftazidime	70.4	9.7	19.9	≤1	16	≤1–>32	
	Ceftriaxone	59.7	1.4	38.9	≤1	>32	≤1–>32	
	Ciprofloxacin	47.7	1.9	50.5	>2	>2	≤0.25–>2	
	Colistin	98.2	–	1.9	≤1	≤1	≤1–4	
	Ertapenem	94.0	0.5	5.6	≤0.06	0.12	≤0.06–>4	
	Imipenem	97.2	1.9	0.9	≤0.5	≤0.5	≤0.5–8	
	Levofloxacin	49.5	3.7	46.8	4	>4	≤1–>4	
	Meropenem	97.2	1.4	1.4	≤0.12	≤0.12	≤0.12–>16	
	Piperacillin-tazobactam	91.7	3.7	4.6	≤2	16	≤2–>64	
	<i>Klebsiella pneumoniae</i> (193)	Ceftolozane–tazobactam	40.4	3.6	56.0	16	>32	0.25–>32
		Amikacin	91.2	1.6	7.3	≤4	16	≤4–>32
Aztreonam		23.8	3.1	73.1	>16	>16	≤1–>16	
Cefepime		25.4	7.8	66.8	>32	>32	≤1–>32	
Cefotaxime		21.8	2.1	76.2	>32	>32	≤1–>32	
Cefoxitin		39.9	10.4	49.7	16	>16	≤2–>16	
Ceftazidime		28.5	2.1	69.4	>32	>32	≤1–>32	
Ceftriaxone		20.7	1.6	77.7	>32	>32	≤1–>32	
Ciprofloxacin		25.9	2.1	72.0	>2	>2	≤0.25–>2	
Colistin		90.2	–	9.8	≤1	2	≤1–>4	
Ertapenem		53.4	1.0	45.6	0.5	>4	≤0.06–>4	
Imipenem		61.1	4.7	34.2	≤0.5	32	≤0.5–>32	
Levofloxacin		28.5	4.7	66.8	>4	>4	≤1–>4	
Meropenem		60.1	2.1	37.8	≤0.12	>16	≤0.12–>16	
Piperacillin-tazobactam		30.6	14.0	55.4	>64	>64	≤2–>64	
Other <i>Enterobacteriales</i> ^a (132)		Ceftolozane–tazobactam	81.1	3.0	15.9	0.5	16	0.12–>32
		Amikacin	90.9	2.3	6.8	≤4	16	≤4–>32
		Aztreonam	72.0	0.8	27.3	≤1	>16	≤1–>16
	Cefepime	62.1	10.6	27.3	≤1	>32	≤1–>32	
	Cefotaxime	52.3	3.0	44.7	≤1	>32	≤1–>32	
	Cefoxitin	56.1	6.1	37.9	8	>16	≤2–>16	
	Ceftazidime	72.7	2.3	25.0	≤1	>32	≤1–>32	
	Ceftriaxone	52.3	5.3	42.4	≤1	>32	≤1–>32	
	Ciprofloxacin	63.6	2.3	34.1	≤0.25	>2	≤0.25–>2	
	Colistin	40.9	–	59.1	>4	>4	≤1–>4	
	Ertapenem	88.6	3.8	7.6	≤0.06	1	≤0.06–>4	
	Imipenem	72.0	18.9	9.1	≤0.5	2	≤0.5–>32	
	Levofloxacin	68.9	4.6	26.5	≤1	>4	≤1–>4	
	Meropenem	93.9	0	6.1	≤0.12	0.25	≤0.12–>16	
	Piperacillin-tazobactam	80.3	7.6	12.1	≤2	>64	≤2–>64	

%S, I, R: percent susceptible, intermediate, resistant by CLSI 2017 guidelines, EUCAST guidelines for colistin were applied for *Enterobacteriales*; MIC₅₀, MIC₉₀, and range in µg/mL; –, no intermediate breakpoint.

^a Other *Enterobacteriales* consist of (n): *Klebsiella aerogenes* (3); *Enterobacter asburiae* (1); *E. cloacae* (38); *Klebsiella oxytoca* (11); *K. variicola* (4); *Morganella morganii* (1); *Proteus mirabilis* (72); *P. vulgaris* (1); *Providencia rettgeri* (1).




Fig. 1 – Frequency distribution (n) of ceftolozane–tazobactam at each MIC (µg/mL) for 132 *Pseudomonas aeruginosa* from Brazil.




Fig. 2 – Frequency distribution (n) of ceftolozane–tazobactam at each MIC (µg/mL) for 216 *Escherichia coli* from Brazil.




Fig. 3 – Frequency distribution (n) of ceftolozane–tazobactam at each MIC (µg/mL) for 193 *Klebsiella pneumoniae* from Brazil.

higher susceptibility to amikacin (91.2%), colistin (90.2%), imipenem (61.1%), meropenem (60.1%), and ertapenem (53.4%) (Table 3; Fig. 3). Other antibiotics have shown inhibition frequencies that ranged from 20.7% to 39.9% (Table 3; Fig. 3).

The analysis performed with other *Enterobacterales* have shown a susceptibility rate to ceftolozane–tazobactam of 81.1% (MIC_{50/90}, 0.5/16 µg/mL). These microorganisms had




Fig. 4 – Frequency distribution (n) of ceftolozane–tazobactam at each MIC (µg/mL) for 132 other* *Enterobacterales* from Brazil.

* Other *Enterobacterales* consist of (n): *Klebsiella aerogenes* (3); *E. asburiae* (1); *E. cloacae* (38); *Klebsiella oxytoca* (11); *K. variicola* (4); *Morganella morganii* (1); *Proteus mirabilis* (72); *P. vulgaris* (1); *Providencia rettgeri* (1).

greater susceptibility to meropenem (93.9%), amikacin (90.9%), and ertapenem (88.6%) – Table 3; Fig. 4.

From 13 ceftolozane/tazobactam non-susceptible *P. aeruginosa* isolates, carbapenemase was detected in 8/13 (62%) isolates which fully explains the detected resistance. The presence of at least one carbapenemase gene was demonstrated in only one isolate (KPC), while the identity of the carbapenemase gene harbored by the remaining 7/8 strains (87.5%) remains unknown and is yet to be studied.

From the remaining five (38%) isolates tested negative for the presence of carbapenemases by Carba-NP, three were randomly chosen to be sequenced aiming to detect previously reported mutations associated to the ceftolozane/tazobactam resistant phenotype.

As expected, genes encoding aminoglycoside modifying enzymes (*aph*(3'-IIb)), chloramphenicol acetyltransferases (*catB7*), and fosfomicin resistance enzymes (*fosA*) were found in all three isolates. Regarding β -lactamases genes, *bla*_{PAO} (*bla*_{AmpC}) and *bla*_{OXA-50} were also detected in all isolates tested.

AmpC substitutions G27D, V205L, and G391A were all found in only one isolate, while substitution T105A was found in two isolates. On the other hand, AmpC substitutions E114A, G283E, and M288R were all detected in only one isolate.

Discussion

This study was conducted aiming to evaluate the activity of ceftolozane–tazobactam against clinical bacterial isolates from Brazil. Thus, *in vitro* analyses were performed and susceptibility of different organisms to several antibiotics are presented.

Microorganisms tested have shown susceptibility rates to ceftolozane–tazobactam ranging from 40.4% (*K. pneumoniae*) to 94.9% (*E. coli*). The susceptibility profile to ceftolozane–tazobactam have varied according with microorganism by intrinsic and extrinsic mechanisms and also according to the country that provided the samples.^{12,16–27} Shortridge et al. assessed the activity of

ceftolozane-tazobactam against Gram-negative isolates from bloodstream infection in the US from 2013 to 2015. In that study, *E. coli* NDM-1, *K. pneumoniae* NDM-1, and *P. aeruginosa* pan- β -lactams non-susceptible (pan-BL-NS) presented complete resistance. *P. aeruginosa* pan-BL-NS were non-susceptible to all β -lactams including ceftolozane-tazobactam. Isolates containing carbapenemases or metallo-beta-lactamases were uncommon (1.4%) in the study, which compromised the robustness of the findings.²⁵ However, three studies have reported susceptibility to ceftolozane-tazobactam that reached 100%, against the following microorganisms: *E. coli* CTX-M 14-like, *E. coli* SHV ESBL, *E. coli* TEM ESBL, *K. pneumoniae* CTX-M 14-like, *Citrobacter koseri*, *Proteus mirabilis* and *Proteus* spp.^{23,25,28} Garcia-Fernandez et al. highlight the activity of ceftolozane-tazobactam against wild type *Enterobacteriales*, although it is dependent on both the species and resistance mechanisms.²⁸ In our study, the susceptibility of *Klebsiella* spp. to ceftolozane-tazobactam was low. This was due to high incidence of carbapenemases in this microorganism, most of them with high rate of hydrolysis of ceftolozane, like KPC. This result suggests that ceftolozane-tazobactam should be used cautiously in empirical therapies considering the high incidence of KPC-producing bacteria. It is important to note that MIC cut-off for *Enterobacteriales* was 1 mg/L, compared to 4 mg/L for *P. aeruginosa*. This is due to higher affinity of ceftolozane to *P. aeruginosa* binding sites.

Regarding the observed susceptibility of *P. aeruginosa*, 84.9% were susceptible to ceftolozane-tazobactam. The same pattern was observed for other *Enterobacteriales*, with susceptibility rates above 80%. These microorganisms represent a great concern for clinical management on community and hospital acquired infections due to its resistance to available antibiotics. Carbapenem resistance observed in *Enterobacteriales*, usually mediated by transferable β -lactamase enzymes, has also become an important issue.²⁹

Some authors have studied the activity of ceftolozane-tazobactam specifically against *P. aeruginosa* and *Enterobacteriales* isolates from Germany, USA, Spain, and Latin America. The frequency of susceptibility rates ranged from 30% to 100% for *P. aeruginosa* and from 77.8% to 100% for *Enterobacteriales*.^{12,18,20,23-26,28} Pfaller et al. reported results of ceftolozane-tazobactam activity against multidrug-resistant *Enterobacteriales* and *P. aeruginosa* from Latin America, including isolates from Brazil. Ceftolozane-tazobactam was the most active of the β -lactam agents tested against *P. aeruginosa* and it was the second most active drug, after meropenem, against *Enterobacteriales*.¹²

Garcia-Fernandez et al. reported the activity of ceftolozane-tazobactam specifically in the context of intensive care units, where a worse pattern of resistance is observed. When *P. aeruginosa* was assessed, a susceptibility rate of 91.3% was observed and it was the third most active, after colistin (95.0%) and amikacin (93.8%). When *Enterobacteriales* were assessed, ceftolozane-tazobactam activity ranged from 5% (carbapenemase-phenotype *K. pneumoniae*) to 100% (*Proteus* spp.),²⁸ which is aligned with the most recent national surveillance findings, where almost 45% of *K. pneumoniae* bloodstream infection isolates were resistant to 3rd and 4th generation cephalosporins and carbapenems.³⁰

Some resistant isolates produce enzymes able to degrade or inactivate β -lactams, such as ESBL samples.³¹ Being a combination of a β -lactam and an inhibitor of a considerable number of β -lactamase enzymes, ceftolozane-tazobactam retains activity against isolates resistant to other β -lactams, sparing the use of meropenem.³²⁻³⁴ It is well known that carbapenem use results in escalating rates of carbapenem-resistant infections, limiting treatment options and increasing mortality.³⁵

In this context, a sub-analysis was performed in order to describe genetic profile of resistant mechanisms in ceftolozane/tazobactam non-susceptible *P. aeruginosa* isolates. The presence of a carbapenemase in most of the isolates is consistent with results previously described in the country.³⁶⁻³⁹ Although one isolate had at least one carbapenemase gene, the remaining still needs further analysis to better address this issue. In Brazil, it is estimated that the frequency of carbapenem-resistant *P. aeruginosa* may reach 40.0% of the observed infections.³⁹⁻⁴² The results shown in the present study highlights the presence of intrinsic mechanisms, and that not all cases of resistance were mediated by transferable carbapenemase-encoding genes. Ceftolozane-tazobactam resistance in non-carbapenemase producing isolates were associated with ampC over-expression by single point mutations in the blaPDC gene (ampC gene) identified by whole gene sequencing. AmpC substitutions G27D, V205L, G391A, T105A, E114A, G283E, and M288R were all associated with AmpC overexpression.

When compared to polymyxins and aminoglycosides, ceftolozane-tazobactam has a greater safety profile.¹ Polymyxins and aminoglycosides are antibiotics with high frequency of toxicity and the last choice when modern antimicrobials are not effective or contraindicated.^{1,43} In a meta-analysis, colistin showed a similar safety profile when compared with other antibiotics in patients with ventilator-associated pneumonia.⁴⁴ However, numerous adverse events, such as mortality, nephrotoxicity, neurotoxicity, allergic and topical reactions, were related with the use of polymyxins, highlighting its toxicity.⁴³ Thus, since ceftolozane-tazobactam has a favorable safety profile, it seems to be a good option in clinical practice.

One study limitation needs to be highlighted: the lack of an alternative test to confirm MIC results of the isolates susceptibility profile. Despite MIC testing recommendation for antimicrobial susceptibility assessment, the study would benefit from using an additional technique or different approach to further investigate that point. Even though, the study provides new information about the activity of this antimicrobial agent against different isolates from Brazil.

As a regional surveillance network that collected 2410 pathogens from selected medical centers, the study does not provide a population-based data, nor information about the incidence of infections in a given region.

In conclusion, ceftolozane-tazobactam has shown satisfactory activity against a great variety of microorganisms analyzed, especially when respiratory tract is the infection site as reported in clinical studies, showing promising results even against resistant strains.^{17,21,45,46}

The activity of ceftolozane-tazobactam is specially observed against *P. aeruginosa*, *E. coli*, and other

Enterobacterales. Our data suggest that ceftolozane-tazobactam may be an important treatment option, including against multidrug resistant strains.

Editorial support

Medical writing was provided by Roberta Arinelli Fernandes, Ana Carolina Padula Ribeiro Pereira and Ayke Adnet de Lima of Sense Company Brazil. This assistance was funded by MSD Brazil.

Authors contribution

All authors were involved in at least one of the following: conception, design of work or acquisition, analysis, interpretation of data and drafting the manuscript and/or revising/reviewing the manuscript for important intellectual content. All authors provided final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflicts of interest

Suellen da Silva Rodrigues, Fernando Brandão Serra, and Marina Della-Negra de Paula, are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, who may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA.

FFT received research grants from MSD, Pfizer and TEVA.

Acknowledgment

This study was supported by Merck Sharpe Dohme.

REFERENCES

- Bassetti M, Russo A, Carmelutti A, La Rosa A, Righi E. Antimicrobial resistance and treatment: an unmet clinical safety need. *Expert Opin Drug Saf.* 2018;17:669–80.
- Centers of Disease Control and Prevention (CDC). About antimicrobial resistance. Available at: <https://www.cdc.gov/drugresistance/about.html>
- Mehrad B, Clark NM, Zhanel GG, Lynch JP. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. *Chest.* 2015;147:1413–21.
- Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed. *JAMA.* 2018;321:2018–9.
- World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017. p. 7.
- Salimi H, Yakhchali B, Owlia P, Lari AR. Molecular epidemiology and drug susceptibility of *Pseudomonas aeruginosa* strains isolated from burn patients. *Lab Med.* 2010;41:540–4.
- Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage *Pseudomonas aeruginosa* infections. *Drugs Cont.* 2018;7:1–18.
- Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious *P. aeruginosa* infections: a multicenter nationwide clinical experience. *Int J Antimicrob Agents.* 2018, <http://dx.doi.org/10.1016/j.ijantimicag.2018.11.001>.
- Brasil. Boletim de Segurança do Paciente e Qualidade em Serviços de Saúde nº 16: Avaliação dos indicadores nacionais das Infecções Relacionadas à Assistência à Saúde (IRAS) e Resistência microbiana do ano de 2016. ANVISA - Segurança Do Paciente E Qual Em Serviços Saúde. 2016;16:83.
- Sorbera M, Chung E, Ho CW, Marzella N. Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections. *P&T.* 2014;39:825–32.
- Martirosov DM, Lodise TP. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. *Diagn Microbiol Infect Dis.* 2016;85:266–75.
- Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015). *Brazilian J Infect Dis.* 2017;21:627–37.
- Clinical Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards. 10 ed. Pennsylvania: CLSI; 2015.
- Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing – twenty-seventh informational supplement. 27 ed. Pennsylvania: CLSI; 2017.
- The European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical breakpoints. Available at: http://www.eucast.org/clinical_breakpoints/
- del Barrio-Tofiño E, López-Causapé C, Cabot G, et al. Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa* isolates from Spain. *Antimicrob Agents Chemother.* 2017;61:1–13.
- Carvalhoes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. *Diagn Microbiol Infect Dis.* 2018, <http://dx.doi.org/10.1016/j.diagmicrobio.2018.11.021>. S0732-8893-5.
- Finklea JD, Hollaway R, Lowe K, Lee F, Le J, Jain R. Ceftolozane/tazobactam sensitivity patterns in *Pseudomonas aeruginosa* isolates recovered from sputum of cystic fibrosis patients. *Diagn Microbiol Infect Dis.* 2018;92:75–7.
- Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham CD. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of β -lactam-resistant gram-negative bacteria. *Ann Lab Med.* 2017;37:174–6.
- Goodlet KJ, Nicolau DP, Nailor MD. In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2017;61:1–12.
- Livermore DM, Mushtaq S, Meunier D, et al. Activity of ceftolozane/tazobactam against surveillance and “problem” Enterobacteriaceae, *Pseudomonas aeruginosa* and non-fermenters from the British Isles. *J Antimicrob Chemother.* 2017;72:2278–89.
- Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and

- urinary tract infections in European and United States hospitals (2012). *J Infect.* 2014;69:266–77.
23. Seifert H, Körber-Irrgang B, Kresken M, et al. In-vitro activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. *Int J Antimicrob Agents.* 2018;51:227–34.
 24. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane–tazobactam activity against *Pseudomonas aeruginosa* clinical isolates from US hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother.* 2017;61:1–6.
 25. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane–tazobactam tested against Enterobacteriaceae and *Pseudomonas aeruginosa* collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane–Tazobactam Susceptibility (PACTS) surveillance program. *Diagn Microbiol Infect Dis.* 2018;92:158–63.
 26. Tato M, García-Castillo M, Bofarull AM, Cantón R. In vitro activity of ceftolozane/tazobactam against clinical isolates of *Pseudomonas aeruginosa* and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. *Int J Antimicrob Agents.* 2015;46:502–10.
 27. Shortridge D, Duncan LR, Pfaller MA, Flamm RK. Activity of ceftolozane–tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the United States and Europe during 2012–2016 as part of a global surveillance programme. *Int J Antimicrob Agents.* 2019, <http://dx.doi.org/10.1016/j.ijantimicag.2019.01.015>.
 28. García-Fernández S, García-Castillo M, Bou G, et al. Activity of ceftolozane–tazobactam against *Pseudomonas aeruginosa* and Enterobacteriales isolates recovered in Intensive Care Units in Spain: the SUPERIOR multicentre study. *Int J Antimicrob Agents.* 2019, <http://dx.doi.org/10.1016/j.ijantimicag.2019.02.004>.
 29. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. *J Intern Med.* 2015;277:501–12.
 30. BRASIL. Ministério da Saúde. Boletim de Segurança do Paciente e Qualidade em Serviços de Saúde nº 16: Avaliação dos indicadores nacionais das Infecções Relacionadas à Assistência à Saúde (IRAS) e Resistência microbiana do ano de 2017. ANVISA – Segurança Do Paciente E Qual Em Serviços Saúde; 2017. Available at: <https://www20.anvisa.gov.br/segurancadopaciente/index.php/publicacoes/item/boletim-seguranca-do-paciente-e-qualidade-em-servicos-de-saude>
 31. Alby K, Miller MB. Mechanisms and detection of antimicrobial resistance. Principles and practice of pediatric infectious diseases. 5th ed. Elsevier; 2018, 1467–78.e4.
 32. Mo Y, Lorenzo M, Farghaly S, Kaur K, Housman ST. What's new in the treatment of multidrug-resistant gram-negative infections? *Diagn Microbiol Infect Dis.* 2019;93:171–81.
 33. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β -lactam/ β -lactamase inhibitor combinations. *Clin Infect Dis.* 2016;63:234–41.
 34. Tamma PD, Hsu AJ. Defining the role of novel β -lactam agents that target carbapenem-resistant gram-negative organisms. *J Pediatric Infect Dis Soc.* 2019;45:846–60.
 35. Codjoe F, Donkor E. Carbapenem resistance: a review. *Med Sci.* 2017;6:1.
 36. Araujo BF, Ferreira ML, De Campos PA, et al. Clinical and molecular epidemiology of multidrug-resistant *P. aeruginosa* carrying *aac(6)-ib-cr*, *qnrS1* and *bla_{SPM}* genes in Brazil. *PLoS One.* 2016;11:1–15.
 37. Dantas RCC, Silva RTE, Ferreira ML, et al. Molecular epidemiological survey of bacteremia by multidrug resistant *Pseudomonas aeruginosa*: the relevance of intrinsic resistance mechanisms. *PLoS One.* 2017;12:1–14.
 38. Dantas RCC. Estudo epidemiológico molecular da resistência aos carbapenêmicos em *Pseudomonas aeruginosa* isoladas de sangue: produção de β -lactamases, perda de porina OprD e hiperexpressão de bombas de efluxo. Universidade Federal de Uberlândia; 2015.
 39. Cacci LC, Chuster SG, Martins N, et al. Mechanisms of carbapenem resistance in endemic *Pseudomonas aeruginosa* isolates after an SPM-1 metallo- β -lactamase producing strain subsided in an intensive care unit of a teaching hospital in Brazil. *Mem Inst Oswaldo Cruz.* 2016;111:551–8.
 40. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). *Diagn Microbiol Infect Dis.* 2012;73:354–60.
 41. Maya JJ, Ruiz SJ, Blanco VM, et al. Current status of carbapenemases in Latin America. *Expert Rev Anti Infect Ther.* 2013;11:657–67.
 42. Kiffer C, Hsiung A, Oplustil C, et al. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. *Brazilian J Infect Dis.* 2005;9:216–24.
 43. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. *Expert Opin Drug Saf.* 2015;14:1687–701.
 44. Florescu DF, Qiu F, Mccartan MA, Mindru C, Fey PD, Kalil AC. What Is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. *Clin Infect Dis.* 2012;54, <http://dx.doi.org/10.1093/cid/cir934>.
 45. Estabrook M, Bussell B, Clugston SL, Bush K. In vitro activity of ceftolozane–tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. *Escherichia coli* isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β -lactamases. *J Clin Microbiol.* 2014;52:4049–52.
 46. Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of ceftolozane–tazobactam and ceftazidime–avibactam against beta-lactam-resistant *Pseudomonas aeruginosa* isolates. *Antimicrob Agents Chemother.* 2017;61:1–4.